EyePoint Pharmaceuticals, Inc (EYPT)

Etorro trading 970x250
EyePoint Pharmaceuticals, Inc (EYPT) Logo

About EyePoint Pharmaceuticals, Inc

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor that is in Phase 1 clinical trials for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts. Address: 480 Pleasant Street, Watertown, MA, United States, 02472

EyePoint Pharmaceuticals, Inc News and around…

Latest news about EyePoint Pharmaceuticals, Inc (EYPT) common stock and company :

EyePoint Pharmaceuticals Presents Preliminary Safety Data from Phase 1 DAVIO Trial and YUTIQ® CALM Registry Study at American Society of Retina Specialists (ASRS) 39th Annual Meeting
12 Oct, 2021 Yahoo! Finance

– 3-month safety data from DAVIO trial continues to demonstrate EYP-1901 is well-tolerated in eyes with wet AMD – – YUTIQ® CALM registry study collecting real-world data on patients with fluocinolone acetonide intravitreal (FAi) implant 0.18 mg is ongoing – WATERTOWN, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders,

Analysts Predict 11% Gains Ahead For DWAS
08 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco DWA SmallCap Momentum ETF (DWAS), we found that the implied analyst target price for the ETF based upon its underlying holdings is $101.18 per unit.

EyePoint Pharmaceuticals' (NASDAQ:EYPT) investors will be pleased with their stellar 114% return over the last year
06 Oct, 2021 Yahoo! Finance

Unfortunately, investing is risky - companies can and do go bankrupt. On the other hand, if you find a high quality...

EyePoint Sets its Sights on Developing Treatments Improving the Lives of Eye Disease Sufferers
30 Sep, 2021 FinancialContent

Photo Credit: EyePoint Pharmaceuticals Companies dedicated to improving the lives of the 2.2 billion people suffering from eye ...

EyePoint Pharmaceuticals to Present Data at the American Academy of Ophthalmology (AAO) 2021 Annual Meeting
17 Sep, 2021 FinancialContent
EyePoint Sets its Sights on Continued Trial Success in Developing Treatments Improving the Lives of Eye Disorder Sufferers
14 Sep, 2021 FinancialContent

Photo by Brands&People on Unsplash Companies dedicated to improving the lives of the 2.2 billion people suffering from eye ...

EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
07 Sep, 2021 FinancialContent
EyePoint Pharmaceuticals to Present at the H.C. Wainwright Ophthalmology Virtual Conference
10 Aug, 2021 FinancialContent
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Released Earnings Last Week And Analysts Lifted Their Price Target To US$20.17
07 Aug, 2021 Yahoo! Finance

EyePoint Pharmaceuticals, Inc. ( NASDAQ:EYPT ) investors will be delighted, with the company turning in some strong...

EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Tops Revenue Estimates
04 Aug, 2021 Yahoo! Finance

EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of 22.22% and 2.42%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

EyePoint Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Corporate Developments
04 Aug, 2021 FinancialContent
EyePoint Pharmaceuticals (NASDAQ:EYPT) Has Debt But No Earnings; Should You Worry?
03 Aug, 2021 Yahoo! Finance

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

EyePoint Pharmaceuticals Announces Renowned Scientists to Join New Executive Scientific Advisory Board
02 Aug, 2021 FinancialContent

Chaired by Dr. Carl Regillo, illustrious leader in retinal surgery

Were Hedge Funds Right About EyePoint Pharmaceuticals, Inc. (EYPT)?
30 Jul, 2021 Yahoo! Finance

Last year we predicted the arrival of the first US recession since 2009 and we told in advance that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each stock […]

EyePoint Pharmaceuticals (EYPT) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
28 Jul, 2021 Yahoo! Finance

EyePoint Pharmaceuticals (EYPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

EyePoint Pharmaceuticals to Report Second Quarter 2021 Financial Results on August 4, 2021
28 Jul, 2021 FinancialContent
EyePoint Pharmaceuticals Receives Preliminary Extension to Pass-Through Payment Status for DEXYCU®
20 Jul, 2021 FinancialContent
RSI Alert: EyePoint Pharmaceuticals (EYPT) Now Oversold
13 Jul, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

EYPT Makes Notable Cross Below Critical Moving Average
06 Jul, 2021 FinancialContent

In trading on Tuesday, shares of EyePoint Pharmaceuticals Inc (EYPT) crossed below their 200 day moving average of $8.32, changing hands as low as $8.26 per share. EyePoint Pharmaceuticals Inc shares are currently trading down about 5.6% on the day..

EyePoint Pharmaceuticals Reports Positive 30-day Safety Results for all Cohorts from the DAVIO Trial of EYP-1901 for wet-AMD
06 Jul, 2021 FinancialContent

Study remains on track to report top line data in Q4 2021

EyePoint Pharmaceuticals Announces New Category III CPT Code for DEXYCU® Intraocular Suspension, Approved by the American Medical Association
01 Jul, 2021 FinancialContent
EyePoint Pharmaceuticals Joins Russell 2000® and Russell 3000® Index
28 Jun, 2021 FinancialContent
EyePoint Pharmaceuticals to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conference
26 May, 2021 FinancialContent
EyePoint Pharmaceuticals Announces Completion of Enrollment of Phase 1 DAVIO Clinical Trial of EYP-1901 for the Potential Treatment of Wet AMD
25 May, 2021 FinancialContent
EyePoint Pharmaceuticals: Q1 Earnings Insights
05 May, 2021 FinancialContent

Shares of EyePoint Pharmaceuticals (NASDAQ:EYPT) moved higher by 2.0% in pre-market trading after the company reported Q1 ...

The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues
05 May, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

EyePoint Pharmaceuticals Reports First Quarter 2021 Financial Results and Highlights Recent Corporate Developments
05 May, 2021 FinancialContent
EyePoint Pharmaceuticals's Earnings Outlook
04 May, 2021 FinancialContent

On Wednesday, May 05, EyePoint Pharmaceuticals (NASDAQ:EYPT) will release its latest earnings report. Decipher the announcement with ...

Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
01 May, 2021 FinancialContent

Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA ...

EyePoint Pharmaceuticals to Report First Quarter 2021 Financial Results and Discuss Recent Corporate Developments on May 5, 2021
28 Apr, 2021 FinancialContent

EyePoint Pharmaceuticals, Inc (EYPT) is a NASDAQ Common Stock listed in , ,

970x250